Please assess the completion status of the following clinical trial:

Trial Title: Enoxaparin and/or Minocycline in Acute Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
There are two Study Sections: A and B~--------------------------------------------~Study Section A Inclusion Criteria:~1. acute ischemic stroke in an adult in-patient who can complete screening and begin study treatment within 6 hours of stroke onset (onset time defined as the last time the patient was known to be at his/her usual level of functioning)~2. patient not a candidate for rTPA treatment because treatment cannot be started within the required 3 hours after stroke onset, or because rTPA treatment is refused.~Study Section A Exclusion Criteria:~1. intracranial hemorrhage;~2. subfalcine, transtentorial, or foramen magnum herniation on CT or MRI scan of the brain;~3. history of hypersensitivity or intolerance to or toxicity from enoxaparin, other heparinoids, heparin, minocycline, or other tetracyclines;~4. weight 125lbs or less;~5. active bleeding;~6. thrombolytic treatment or major surgery in the previous 24 hours;~7. anticipated need for treatment with coumarin, or a low-molecular weight heparin other than enoxaparin, or unfractionated heparin before 36 hours after stroke onset (but see deep venous thrombosis prophylaxis, below);~8. INR above the normal range;~9. known coagulopathy;~10. platelet count \<100,000/mm3 (if the count drops below 100,000 while on enoxaparin, the medication will be stopped)~11. pregnancy or lactation;~12. undergoing dialysis; severe renal impairment (creatinine clearance known or estimated to be \<30ml/min);~13. mean arterial BP (taken to be 1/3 of the difference in mm Hg between diastolic BP and systolic BP, added to the diastolic BP) of 130 mm Hg or greater; (if the mean arterial BP is 130 mm Hg or greater but can be reduced by treatment to \< 130 mm Hg, with systolic BP in the 150 169 mm Hg range, the patient may be entered).~Patients in Study Section A will be randomly assigned to one of the four treatment arms: enoxaparin, minocycline, enoxaparin and minocycline, or no intervention.~--------------------------------------------~Study Section B Inclusion Criteria:~1. acute ischemic stroke in an adult in-patient who can complete screening and begin study treatment within 24 hours of stroke onset (onset time defined as the last time the patient was known to be at his/her usual level of functioning;)~2. patient does not qualify for, or declines to participate in, Study Section A.~Study Section B Exclusion Criteria:~1. acute primary intracranial hemorrhage;~2. subfalcine, transtentorial, or foramen magnum herniation on CT or MRI scan of the brain;~3. pregnancy or lactation.~Patients in Study Section B will be randomly assigned to one of TWO treatment arms: minocycline, or no intervention.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- Enoxaparin (Type: EXPERIMENTAL): None
- Minocycline (Type: EXPERIMENTAL): Minocycline 200 mg orally once daily for 5 days
- Enoxaparin and minocycline (Type: EXPERIMENTAL): None
- Control (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues